Skip to main content
SpringerLink
Log in
Book cover

Molecular Pathology of Endocrine Diseases pp 95–101Cite as

Poorly Differentiated and Undifferentiated Thyroid Carcinomas

  • Chapter
  • First Online:

Part of the book series: Molecular Pathology Library ((MPLB,volume 3))

Abstract

The definition of poorly differentiated thyroid carcinoma has been the source of great controversy in the pathology literature.1 Many definitions and schemes have been proposed, but little consensus exists about what defines a poorly differentiated thyroid carcinoma (PDTCA). Because of this, the clinical behavior is not well defined and the clinicopathologic features affecting prognosis remain largely unknown.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Volante M, Collini P, Nikiforov Y, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31(8):1256–1264.

    Article  PubMed  Google Scholar 

  2. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg. 1997;174(5):462–468.

    Article  PubMed  CAS  Google Scholar 

  3. Akslen LA, LiVolsi VA. Poorly differentiated thyroid carcinoma - it is important. Am J Surg Pathol. 2000;24(2):310–313.

    Article  PubMed  CAS  Google Scholar 

  4. Patel KN, Shaha AR. Locally advanced thyroid cancer. Curr Opin Otolaryngol Head Neck Surg. 2005;13(2):112–116.

    Article  PubMed  Google Scholar 

  5. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol. 2005;63(1):87–93.

    Article  CAS  Google Scholar 

  6. Volante M, Landolfi S, Chiusa P, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. 2004;100(5):950–957.

    Article  PubMed  Google Scholar 

  7. Nishiyama RH. Another dissertation on poorly differentiated carcinomas: is it really necessary? Adv Anat Pathol. 1999;6(5):281–286.

    Article  PubMed  CAS  Google Scholar 

  8. Albores-Saavedra J, Carrick K. Where to set the threshold between well differentiated and poorly differentiated follicular carcinomas of the thyroid. Endocr Pathol. 2004;15(4):297–305.

    Article  PubMed  Google Scholar 

  9. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330–1335.

    Article  PubMed  Google Scholar 

  10. Sanders Jr EM, Jr LiVolsi V, Brierly J, et al. An evidence-based review of poorly differentiated thyroid cancer. World J Surg. 2007;31(5):934–945.

    Article  PubMed  Google Scholar 

  11. Pilotti S, Collini P, Mariani L, et al. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin Diagn Pathol. 1995;12(3):249–255.

    PubMed  CAS  Google Scholar 

  12. Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol. 2004;86(1):44–54.

    Article  PubMed  Google Scholar 

  13. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983;52(10):1849–1855.

    Article  PubMed  CAS  Google Scholar 

  14. Yamashita H, Noguchi Y, Noguchi S, et al. Significance of an insular component in follicular thyroid carcinoma with distant metastasis at initial presentation. Endocr Pathol. 2005;16(1):41–48.

    Article  PubMed  Google Scholar 

  15. Volante M, Cavallo GP, Papotti M. Prognostic factors of clinical interest in poorly differentiated carcinomas of the thyroid. Endocr Pathol. 2004;15(4):313–317.

    Article  PubMed  Google Scholar 

  16. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans’ “wuchernde Struma”. Am J Surg Pathol. 1984;8(9):655–668.

    Article  PubMed  CAS  Google Scholar 

  17. Chao TC, Lin JD, Chen MF. Insular carcinoma: infrequent subtype of thyroid cancer with aggressive clinical course. World J Surg. 2004;28(4):393–396.

    Article  PubMed  Google Scholar 

  18. Pilotti S, Collini P, Mariani L, et al. Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol. 1997;21(12):1466–1473.

    Article  PubMed  CAS  Google Scholar 

  19. Falvo L, Catania A, Diandrea V, et al. Prognostic factors of insular versus papillary/follicular thyroid carcinoma. Am Surg. 2004;70(5):461–466.

    PubMed  Google Scholar 

  20. Collini P, Sampietro G, Rosai J, et al. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch. 2003;442(1):71–76.

    PubMed  Google Scholar 

  21. Sobrinho-Simoes M, Sambade C, Fonseca E, et al. Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol. 2002;10(2):123–131.

    Article  PubMed  Google Scholar 

  22. Sasaki A, Daa T, Kashima K, et al. Insular component as a risk factor of thyroid carcinoma. Pathol Int. 1996;46(12):939–946.

    Article  PubMed  CAS  Google Scholar 

  23. Hiltzik DD, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. 2006;106(6):1286–1295.

    Article  PubMed  Google Scholar 

  24. Lam KY, Lo CY, Chan KW, et al. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg. 2000;231(3):329–338.

    Article  PubMed  CAS  Google Scholar 

  25. Takeuchi Y, Das T, Kashima K, et al. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid. 1999;9(4):377–381.

    Article  PubMed  CAS  Google Scholar 

  26. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369(9574):1731–1741.

    Article  PubMed  CAS  Google Scholar 

  27. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev. 2007;17(1):3–7.

    Article  PubMed  CAS  Google Scholar 

  28. Broecker-Preuss M, Sheiu SY, Worm K, et al. Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma. Horm Metab Res. 2008;40(10):685–691.

    Article  PubMed  CAS  Google Scholar 

  29. Pulcrano M, Boukheris H, Talbot M, et al. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid. 2007;17(7):639–646.

    Article  PubMed  Google Scholar 

  30. Montero-Conde C, Martin-Campos JM, Lerma E, et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene. 2008;27(11):1554–1561.

    Article  PubMed  CAS  Google Scholar 

  31. Rodrigues RF, Roque L, King T, et al. Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. Br J Cancer. 2007;96(8):1237–1245.

    Article  PubMed  CAS  Google Scholar 

  32. Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 2007;14(2):719–729.

    Article  PubMed  Google Scholar 

  33. Tallini G, Garcia-Rostan G, Herreo A, et al. Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol. 1999;23(6):678–685.

    Article  PubMed  CAS  Google Scholar 

  34. Garcia-Rostan G, Camp RL, Herrero A, et al. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 2001;158(3):987–996.

    PubMed  CAS  Google Scholar 

  35. Garcia-Rostan G, Tallini G, Herrero A, et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59(8):1811–1815.

    PubMed  CAS  Google Scholar 

  36. Smith LW. Certain so-called sarcomas of the thyroid. Arch Pathol. 1930;10:524–530.

    Google Scholar 

  37. Hutter RV, Tollefson HR, DeCosse J, et al. Spindle and giant cell metaplasia in papillary carcinoma of the thyroid. Am J Surg. 1965;110(4):660–668.

    Article  PubMed  CAS  Google Scholar 

  38. Maddox WA, Knott HW, Dowling EA. Carcinoma of the thyroid: review of fifteen years’ experience. 1. Origin of spindle and giant cell carcinoma. 2. Occurrence of thyroid cancer in ectopic thyroid tissue. Am Surg. 1971;37(11):653–660.

    PubMed  CAS  Google Scholar 

  39. Bronner MP, LiVolsi VA. Spindle cell squamous carcinoma of the thyroid: an unusual anaplastic tumor associated with tall cell papillary cancer. Mod Pathol. 1991;4(5):637–643.

    PubMed  CAS  Google Scholar 

  40. Wolf BC, Sheahan K, DeCosste D, et al. Immunohistochemical analysis of small cell tumors of the thyroid gland: an Eastern Cooperative Oncology Group study. Hum Pathol. 1992;23(11):1252–1261.

    Article  PubMed  CAS  Google Scholar 

  41. Mendelsohn G, Baylin SB, Bigner SH, et al. Anaplastic variants of medullary thyroid carcinoma: a light-microscopic and immunohistochemical study. Am J Surg Pathol. 1980;4(4):333–341.

    Article  PubMed  CAS  Google Scholar 

  42. O’Neill JP, O’Neill B, Conaron C, et al. Anaplastic (undifferen­tiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease. J Laryngol Otol. 2005;119(8):585–591.

    PubMed  Google Scholar 

  43. Jiang JY, Tseng FY. Prognostic factors of anaplastic thyroid carcinoma. J Endocrinol Invest. 2006;29(1):11–17.

    PubMed  CAS  Google Scholar 

  44. Aratake Y, Nomura H, Katami T, et al. Coexistent anaplastic and differentiated thyroid carcinoma. Am J Clin Pathol. 2006;125(3):399–406.

    Google Scholar 

  45. Hunt JL. Unusual thyroid tumors: a review of pathologic and molecular diagnosis. Expert Rev Mol Diagn. 2005;5(5):725–734.

    Article  PubMed  CAS  Google Scholar 

  46. Besic N, Hocevar M, Zogjnar J, et al. Prognostic factors in anaplastic carcinoma of the thyroid - a multivariate survival analysis of 188 patients. Langenbecks Arch Surg. 2005;390(3):203–208.

    Article  PubMed  Google Scholar 

  47. Goutsouliak V, Hay JH. Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol (R Coll Radiol). 2005;17(2):75–78.

    CAS  Google Scholar 

  48. Yau T, Lo CY, Epstein RJ, et al. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol. 2008;15(9):2500–2505.

    Article  PubMed  Google Scholar 

  49. Lai ML, Faa G, Senes C, et al. Rhabdoid tumor of the thyroid gland: a variant of anaplastic carcinoma. Arch Pathol Lab Med. 2005;129(3):e55-e57.

    PubMed  Google Scholar 

  50. Carda C, Ferrer J, Vilanova M, et al. Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases. Virchows Arch. 2005;446(1):46–51.

    Article  PubMed  Google Scholar 

  51. Sato K, Waseda R, Tatsuzawa Y, et al. Papillary thyroid carcinoma with anaplastic transformation showing a rhabdoid phenotype solely in the cervical lymph node metastasis. Pathol Res Pract. 2006;202(1):55–59.

    Article  PubMed  Google Scholar 

  52. Carcangiu ML, Steeper T, Zampi G, et al. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985;83(2):135–158.

    PubMed  CAS  Google Scholar 

  53. Shikama Y, Mizukami H, Yagihashi N, et al. Spindle cell metaplasia arising in thyroid adenoma: characterization of its pathology and differential diagnosis. J Endocrinol Invest. 2006;29(2):168–171.

    PubMed  CAS  Google Scholar 

  54. Aker FV, Bas Y, Ozkara S, et al. Spindle cell metaplasia in follicular adenoma of the thyroid gland: case report and review of the literature. Endocr J. 2004;51(5):457–461.

    Article  PubMed  Google Scholar 

  55. Vergilio J, Baloch ZW, LiVolsi VA. Spindle cell metaplasia of the thyroid arising in association with papillary carcinoma and follicular adenoma. Am J Clin Pathol. 2002;117(2):199–204.

    Article  PubMed  Google Scholar 

  56. Baloch ZW, Wu H, LiVolsi VA. Post-fine-needle aspiration spindle cell nodules of the thyroid (PSCNT). Am J Clin Pathol. 1999;111(1):70–74.

    PubMed  CAS  Google Scholar 

  57. Chan JK, Carcangiu ML, Rosai J. Papillary carcinoma of thyroid with exuberant nodular fasciitis-like stroma: report of three cases. Am J Clin Pathol. 1991;95(3):309–314.

    PubMed  CAS  Google Scholar 

  58. Naganuma H, Iwama N, Nakamura Y, et al. Papillary carcinoma of the thyroid gland forming a myofibroblastic nodular tumor: report of two cases and review of the literature. Pathol Int. 2002;52(1):54–58.

    Article  PubMed  Google Scholar 

  59. Wan SK, Chan JK, Tang SK. Paucicellular variant of anaplastic thyroid carcinoma. A mimic of Reidel’s thyroiditis. Am J Clin Pathol. 1996;105(4):388–393.

    PubMed  CAS  Google Scholar 

  60. Roka S, Kojnek G, Schuller J, et al. Carcinoma showing thymic-like elements - a rare malignancy of the thyroid gland. Br J Surg. 2004;91(2):142–145.

    Article  PubMed  CAS  Google Scholar 

  61. Dorfman DM, Shahsafaei A, Miyauchi A. Intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) exhibits CD5 immunoreactivity: new evidence for thymic differentiation. Histopathology. 1998;32(2):104–109.

    Article  PubMed  CAS  Google Scholar 

  62. Berezowski K, Grimes M, Gal AA, et al. CD5 immunorea-ctivity of epithelial cells in thymic carcinoma and CASTLE using paraffin-embedded tissue. Am J Clin Pathol. 1996;106(4):483–486.

    PubMed  CAS  Google Scholar 

  63. Chan JK, Rosai J. Tumors of the neck showing thymic or related branchial pouch differentiation: a unifying concept. Hum Pathol. 1991;22(4):349–367.

    Article  PubMed  CAS  Google Scholar 

  64. Erickson ML, Tapia E, Moreno ER, et al. Early metastasizing spindle epithelial tumor with thymus-like differentiation (SETTLE) of the thyroid. Pediatr Dev Pathol. 2005;8(5):599–606.

    Article  PubMed  Google Scholar 

  65. Booya F, Sebo TJ, Kasperbauer JL, et al. Primary squamous cell carcinoma of the thyroid: report of ten cases. Thyroid. 2006;16(1):89–93.

    Article  PubMed  Google Scholar 

  66. Rodriguez I, Ayala E, Caballero C, et al. Solitary fibrous tumor of the thyroid gland: report of seven cases. Am J Surg Pathol. 2001;25(11):1424–1428.

    Article  PubMed  CAS  Google Scholar 

  67. Papi G, Corrado S, LiVolsi VA. Primary spindle cell lesions of the thyroid gland: an overview. Am J Clin Pathol. 2006;125(suppl):S95-S123.

    PubMed  Google Scholar 

  68. Miettinen M, Franssila KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol. 2000;31(9):1139–1145.

    Article  PubMed  CAS  Google Scholar 

  69. Nonaka D, Dhiriboga L, Soslow R, et al. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008;21(2):192–200.

    PubMed  CAS  Google Scholar 

  70. Elliott DD, Sherman SL, Bussaldy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39(1):15–20.

    Article  PubMed  CAS  Google Scholar 

  71. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol. 2004;15(4):319–327.

    Article  PubMed  CAS  Google Scholar 

  72. Begum S, Rosenbaum E, Henrique R, et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol. 2004;17(11):1359–1363.

    Article  PubMed  CAS  Google Scholar 

  73. Hunt JL, Tometsko M, LiVolsi V, et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol. 2003;27(12):1559–1564.

    Article  PubMed  Google Scholar 

  74. Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res. 2008;6(5):751–759.

    Article  PubMed  CAS  Google Scholar 

  75. Leboeuf R, Baumgartner JE, Benezra M, et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 2008;93(6):2194–2201.

    Article  PubMed  CAS  Google Scholar 

  76. Hoffmann S, Burchert A, Weinderlich A, et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine. 2007;31(2):105–113.

    Article  PubMed  CAS  Google Scholar 

  77. Pennell NA, Daniels GH, Haddad Ri, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18(3):317–323.

    Article  PubMed  CAS  Google Scholar 

  78. Stenner F, Liewen H, Zweller M, et al. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 2008;99(9):1847–1852.

    PubMed  CAS  Google Scholar 

  79. Salvatore G, DeFalco V, Salerno P, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res. 2006;12(5):1623–1629.

    Article  PubMed  CAS  Google Scholar 

  80. Quiros RM, Ding H, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103(11):2261–2268.

    Article  PubMed  CAS  Google Scholar 

  81. Nikiforova MN, Kimura EJ, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399–5404.

    Article  PubMed  CAS  Google Scholar 

  82. Wang HM, Huang YU, Huang JS, et al. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol. 2007;14(10):3011–3018.

    Article  PubMed  Google Scholar 

  83. Santarpia L, El Naggar AK, Cote G, et al. PI3K/Akt and Ras/Raf-MAPK pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008;93(1):278–284.

    Article  PubMed  CAS  Google Scholar 

  84. Costa AM, Herrerro A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2008;68(4):618–634.

    Article  CAS  Google Scholar 

  85. Rodrigues RF, Roque L, Rosa-Santos J, et al. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer. 2004;90(2):492–496.

    Article  PubMed  CAS  Google Scholar 

  86. Miura D, Wada N, Chin K, et al. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization. Thyroid. 2003;13(3):283–290.

    Article  PubMed  CAS  Google Scholar 

  87. Lee JJ, Au AY, Foukakis J, et al. Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocr Relat Cancer. 2008;15(3):801–815.

    Article  PubMed  CAS  Google Scholar 

  88. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106–3116.

    Article  PubMed  CAS  Google Scholar 

  89. Kitamura Y, Ahimiu K, Ito K, et al. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer. 2000;27(3):244–251.

    Article  PubMed  CAS  Google Scholar 

  90. Fagin JA, Matsuo L, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 1993;91(1):179–184.

    Article  PubMed  CAS  Google Scholar 

  91. Sera N, Ashizawa K, Ando T, et al. Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (131I) therapy. Thyroid. 2000;10(11):975–979.

    Article  PubMed  CAS  Google Scholar 

  92. Hosal SA, Apel R, Freeman JL, et al. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocr Pathol. 1997;8(1):21–28.

    Article  PubMed  Google Scholar 

  93. Salvatore D, Celletti A, Fabien N, et al. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol. 1996;134(2):177–183.

    Article  PubMed  CAS  Google Scholar 

  94. Zafon C, Obois G, Castelivi J, et al. Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology. 2007;50(2):225–231.

    Article  PubMed  CAS  Google Scholar 

  95. Nakamura N, Carney Ja, Jin L, et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 2005;85(9):1065–1075.

    Article  PubMed  CAS  Google Scholar 

  96. Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004;64(5):1664–1668.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA

    Jennifer L. Hunt MD, MEd (Associate Chief of Pathology, Director of Quality and Safety, Associate Professor of Pathology)

  2. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Virginia A. LiVolsi MD (Professor)

Authors
  1. Jennifer L. Hunt MD, MEd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Virginia A. LiVolsi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pathology Service, WRN202, Massachusetts General Hospital, Fruit Street 55, Boston, 02114, USA

    Jennifer L. Hunt

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hunt, J.L., LiVolsi, V.A. (2010). Poorly Differentiated and Undifferentiated Thyroid Carcinomas. In: Hunt, J. (eds) Molecular Pathology of Endocrine Diseases. Molecular Pathology Library, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1707-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1707-2_10

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-1706-5

  • Online ISBN: 978-1-4419-1707-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation